Reirradiation With Robotic Stereotactic Body Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma

Dizman, Aysen; Coskun, M.; Güney, Yıldız; Karakaya, Ebru; Olcay, G.

doi:10.1016/j.ijrobp.2013.06.1932

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another finding was that 125 I brachytherapy for recurrent NPC achieved better local control, LTPFS was significantly better in group A than in group B. Dizman et al reported progression free survival and OS of recurrent NPC treated with stereotactic body radiation therapy at 1-, 2- and 3-years were 60%, 30%, 17% and 83%, 43%, 31%, respectively 39 . The group B results in this study were similar.…”

Section: Discussionmentioning

confidence: 98%

CT-guided ¹²⁵I brachytherapy for locally recurrent nasopharyngeal carcinoma

Yan¹,

Mo²,

Xiang³

et al. 2017

J. Cancer

View full text Add to dashboard Cite

Purpose: The study evaluated the feasibility, clinical effectiveness, and quality of life of computed tomography (CT)-guided 125 I brachytherapy for locally recurrent nasopharyngeal carcinoma (NPC). Methods: We recruited 81 patients diagnosed with locally recurrent NPC after previous radiotherapy with or without chemotherapy. Thirty-nine patients received 125 I brachytherapy (group A) and 42 received re-irradiation (IMRT, group B). The evaluated outcomes were local control, complications, and quality of life. Cox proportional hazards regression analysis was used to compare local tumor progression-free survival (LTPFS) and overall survival (OS) in the two treatment groups. Results: The median follow-up was 30 months (range, 5-68 months), median LTPFS was 21 in group A and 17 months in group B. The 1-, 2-, and 3-year OS in group A were 84.6%, 51.3%, 30.7%, and 85.7%, 50.0%, and 32.6% in group B. In group A, 10/39 patients (25.6%) experienced at least one ≥grade III complication; no grade V complications occurred. In group B, 28/42 (66.7%) experienced at least one ≥grade III complication and 6/42 (14.3%) died of severe grade V complications. No significant between-group difference existed in the Quality of Life score on the EORTC QLQ-H&N35 questionnaire before treatment. In group A, quality of life was significantly improved after treatment; but did not improve, or even deteriorated in group B. Conclusions:125 I brachytherapy was a feasible, safe, and effective treatment for locally recurrent NPC.125 I brachytherapy significantly reduced complications caused by re-irradiation and improved patients' quality of life.

show abstract

Section: Discussionmentioning

confidence: 98%

CT-guided ¹²⁵I brachytherapy for locally recurrent nasopharyngeal carcinoma

Yan¹,

Mo²,

Xiang³

et al. 2017

J. Cancer

View full text Add to dashboard Cite

show abstract

Outcomes for the treatment of locoregional recurrent nasopharyngeal cancer: Systematic review and pooled analysis

et al. 2021

View full text Add to dashboard Cite

Despite advances in the treatment of primary nasopharyngeal carcinoma, locoregional recurrence (lrNPC) occurs at 10%-50% at 5 years. This review aims to evaluate salvage treatment for locally recurrent nasopharyngeal cancer. A literature search for all original articles published on the treatment of lrNPC from January 1990 to January 2021 was conducted. Pooled analysis was performed using a random effects model and assessed statistical heterogeneity of the combined results with I 2 index. Overall, 66 studies were included for analysis. A total of 5286 patients treated with intensity-modulated radiation therapy (39%), conformal radiotherapy (31%), open nasopharyngectomy (12%), endoscopic nasopharyngectomy (10%), stereotactic radiosurgery (4%), and brachytherapy (4%) were included. Surgical therapy has similar overall survival outcomes to re-irradiation but with decreased treatment-related morbidity and mortality. Both surgical and re-irradiation for lrNPC have similar long-term survival. Surgical approaches to lrNPC may offer similar survival while avoiding treatment-associated morbidity and mortality.

show abstract

Reirradiation With Robotic Stereotactic Body Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma

Cited by 2 publications

References 0 publications

CT-guided ¹²⁵I brachytherapy for locally recurrent nasopharyngeal carcinoma

CT-guided ¹²⁵I brachytherapy for locally recurrent nasopharyngeal carcinoma

Outcomes for the treatment of locoregional recurrent nasopharyngeal cancer: Systematic review and pooled analysis

Contact Info

Product

Resources

About

Reirradiation With Robotic Stereotactic Body Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma

Cited by 2 publications

References 0 publications

CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma

CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma

Outcomes for the treatment of locoregional recurrent nasopharyngeal cancer: Systematic review and pooled analysis

Contact Info

Product

Resources

About

CT-guided ¹²⁵I brachytherapy for locally recurrent nasopharyngeal carcinoma

CT-guided ¹²⁵I brachytherapy for locally recurrent nasopharyngeal carcinoma